Description
XL-228 is a third generation inhibitor of Abl that shows efficacy in a variety of cell lines, including those exhibiting T315I mutations. XL-228 displays anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for chronic myelogenous leukemia (CML).